Biofrontera Inc
BFRI
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.95M
Close$
$-0.25
130% downside
Current Fair Value
130% downsideOvervalued by 130% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.95 Million |
|---|---|
| Enterprise Value | $13.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.04 |
| Beta | 0.88 |
| Outstanding Shares | 12,923,710 |
Return
| Return on Equity | -106.87% |
|---|---|
| Return on Assets | -26.45% |
| Return on Invested Capital | -50.93% |
Valuation & Multiples
| P/E Ratio | -1.62 |
|---|---|
| PEG | 1.82 |
| Price to Sales | 0.28 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.3 |
| Enterprise Value to EBIT | -2 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | 1.26 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$9.50 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.22
Average shareholder expectationRevenue Estimate
$8.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 21.37%▲ 0.89% |
|---|---|
| Total Invested | $2.61M▲ 34.87% |
| Investors Holding | 19▲ 7.00% |
ESG Score
No data
About Biofrontera Inc
82 employees
CEO: Hermann Lübbert Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company off...